Centessa Pharmaceuticals Plc Stock Performance
| CNTA Stock | USD 17.10 0.06 0.35% |
On a scale of 0 to 100, Centessa Pharmaceuticals holds a performance score of 9. The firm shows a Beta (market volatility) of 1.24, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Centessa Pharmaceuticals will likely underperform. Please check Centessa Pharmaceuticals' total risk alpha, downside variance, daily balance of power, as well as the relationship between the maximum drawdown and skewness , to make a quick decision on whether Centessa Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Centessa Pharmaceuticals PLC are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unsteady basic indicators, Centessa Pharmaceuticals sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 4.87 | Five Day Return 5.3 | Year To Date Return 122.54 | Ten Year Return (17.84) | All Time Return (17.84) |
1 | Disposition of 11742 shares by Weinhoff Gregory M of Centessa Pharmaceuticals at 6.47 subject to Rule 16b-3 | 08/30/2024 |
2 | Disposition of 25000 shares by Weinhoff Gregory M of Centessa Pharmaceuticals at 15.0 subject to Rule 16b-3 | 09/09/2024 |
3 | Centessa Pharmaceuticals prices 225M equity offfering | 09/13/2024 |
4 | Disposition of 16619 shares by Weinhoff Gregory M of Centessa Pharmaceuticals at 15.6883 subject to Rule 16b-3 | 09/25/2024 |
5 | Nantahala Capital Management LLC Buys Shares of 450,000 Centessa Pharmaceuticals plc - MarketBeat | 10/01/2024 |
6 | Disposition of 22205 shares by Saha Saurabh of Centessa Pharmaceuticals at 15.801 subject to Rule 16b-3 | 10/21/2024 |
7 | Disposition of 30203 shares by Saha Saurabh of Centessa Pharmaceuticals at 15.6663 subject to Rule 16b-3 | 10/22/2024 |
8 | Disposition of 2592 shares by Saha Saurabh of Centessa Pharmaceuticals at 15.3151 subject to Rule 16b-3 | 10/23/2024 |
9 | Disposition of 11742 shares by Weinhoff Gregory M of Centessa Pharmaceuticals at 15.3831 subject to Rule 16b-3 | 10/25/2024 |
10 | Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update | 11/12/2024 |
11 | Disposition of 32023 shares by Saha Saurabh of Centessa Pharmaceuticals at 18.2812 subject to Rule 16b-3 | 11/13/2024 |
12 | Is Centessa Pharmaceuticals Using Debt Sensibly | 11/14/2024 |
13 | Guggenheim lifts Centessa Pharma stock target, keeps buy on developments | 11/15/2024 |
14 | Disposition of 3511 shares by Saha Saurabh of Centessa Pharmaceuticals at 18.2365 subject to Rule 16b-3 | 11/21/2024 |
15 | Centessa Pharmaceuticals Shares Down 4.5 percent Time to Sell | 11/22/2024 |
| Begin Period Cash Flow | 393.6 M |
Centessa |
Centessa Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,348 in Centessa Pharmaceuticals PLC on August 28, 2024 and sell it today you would earn a total of 362.00 from holding Centessa Pharmaceuticals PLC or generate 26.85% return on investment over 90 days. Centessa Pharmaceuticals PLC is currently generating 0.4539% in daily expected returns and assumes 3.9548% risk (volatility on return distribution) over the 90 days horizon. In different words, 35% of stocks are less volatile than Centessa, and 91% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Centessa Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Centessa Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Centessa Pharmaceuticals PLC, and traders can use it to determine the average amount a Centessa Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1148
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CNTA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.95 actual daily | 35 65% of assets are more volatile |
Expected Return
| 0.45 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 9 91% of assets perform better |
Based on monthly moving average Centessa Pharmaceuticals is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Centessa Pharmaceuticals by adding it to a well-diversified portfolio.
Centessa Pharmaceuticals Fundamentals Growth
Centessa Stock prices reflect investors' perceptions of the future prospects and financial health of Centessa Pharmaceuticals, and Centessa Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Centessa Stock performance.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.2 | ||||
| Operating Margin | (23.59) % | ||||
| Current Valuation | 1.81 B | ||||
| Shares Outstanding | 131.84 M | ||||
| Price To Book | 4.50 X | ||||
| Price To Sales | 327.83 X | ||||
| Revenue | 6.85 M | ||||
| EBITDA | (166.07 M) | ||||
| Net Income | (151.09 M) | ||||
| Cash And Equivalents | 484.16 M | ||||
| Cash Per Share | 5.13 X | ||||
| Total Debt | 84.59 M | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 15.48 X | ||||
| Book Value Per Share | 4.29 X | ||||
| Cash Flow From Operations | (160.34 M) | ||||
| Earnings Per Share | (1.52) X | ||||
| Market Capitalization | 2.25 B | ||||
| Total Asset | 360.25 M | ||||
| Retained Earnings | (752.95 M) | ||||
| Working Capital | 275.71 M | ||||
About Centessa Pharmaceuticals Performance
By analyzing Centessa Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Centessa Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Centessa Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Centessa Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.53) | (0.56) | |
| Return On Assets | (0.42) | (0.44) | |
| Return On Equity | (0.64) | (0.67) |
Things to note about Centessa Pharmaceuticals performance evaluation
Checking the ongoing alerts about Centessa Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Centessa Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Centessa Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 6.85 M. Net Loss for the year was (151.09 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Centessa Pharmaceuticals PLC currently holds about 484.16 M in cash with (160.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.13. | |
| Centessa Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 93.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Centessa Pharmaceuticals Shares Down 4.5 percent Time to Sell |
- Analyzing Centessa Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Centessa Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Centessa Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Centessa Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Centessa Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Centessa Pharmaceuticals' stock. These opinions can provide insight into Centessa Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Centessa Stock analysis
When running Centessa Pharmaceuticals' price analysis, check to measure Centessa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Centessa Pharmaceuticals is operating at the current time. Most of Centessa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Centessa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Centessa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Centessa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |